User banner image
User avatar
  • admin

Posts

Sandmark Crypto Intelligence Report Shows Credible Insight Drives Investment Confidence

38% of finance professionals who personally hold crypto view it as a growth opportunity with strong upside potential 96% of professional investors are optimistic about crypto’s future...

FDA Accepts NDA for TLX101-Px (Pixclara®)

MELBOURNE, Australia and INDIANAPOLIS, April 10, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food...

Open Source, After Mythos

By Rob Thomas | Senior Vice President, IBM Software and Chief Commercial Officer ARMONK, N.Y., April 10, 2026 /PRNewswire/ — There is a pattern we keep...

INTRODUCING NATURE’S WELLNESS SANCTUARY AT 1 HOTEL HANALEI BAY

A Next-Generation Wellness Destination on the North Shore of Kauaʻi KAUAʻI, Hawaiʻi, April 10, 2026 /PRNewswire/ — 1 Hotel Hanalei Bay announces the debut of...

GEN Korean BBQ To Sell All Products at 190 Grocery Stores

GEN Korean BBQ Expands KBBQ Meat & Restaurant Experience with Launch of New Retail Products Inspired by Fan-Favorite Flavors CERRITOS, Calif., April 09, 2026 (GLOBE...

Valitor to Participate in the 25th Annual Needham Virtual Healthcare Conference

BERKELEY, Calif., April 09, 2026 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced that chief executive officer Gregory...

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive DIFS approach Publication adds...

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor...

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipeline HOUSTON,...

AMN Healthcare to Hold First Quarter 2026 Earnings Conference Call on Thursday, May 7, 2026

DALLAS, April 09, 2026 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2026 financial...